Evidence map›Paper›PMID 38114923›Full record

ArticleBMC nephrology2023

Machine learning models to predict end-stage kidney disease in chronic kidney disease stage 4.

Kullaya Takkavatakarn, Wonsuk Oh, Ella Cheng, Girish N Nadkarni, Lili Chan

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Kullaya TakkavatakarnDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wonsuk OhThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ella ChengThe Cooper Union for the Advancement of Science and Art, New York, NY, USA.
Girish N Nadkarni *Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. girish.nadkarni@mountsinai.org.
Lili Chan *Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. lili.chan@mountsinai.org.
Icahn School of Medicine at Mount Sinai · USChulalongkorn University · THCooper Union · US

Funding

Incorporating genomics into the clinical care of diverse NYC childrenU01HG009610 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GELB, BRUCE D, HOROWITZ, CAROL R · 2017 to 2021
$17.0M
Multi-Omics and Chronic Kidney Disease: Correlation with HistologyR01DK108803 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Morgan Erika Grams, EUGENE P. RHEE · 2016 to 2026
$6.4M
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary CareU01HG007278 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOROWITZ, CAROL R · 2013 to 2018
$5.7M
Mount Sinai Nephrology Research Training GrantT32DK007757 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CAMPBELL, KIRK N, HE, JOHN CIJIANG · 1998 to 2022
$3.8M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
Improving risk prediction of adverse outcomes in hemodialysis patients by incorporating non-traditional risk factorsK23DK124645 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHAN, LILI · 2021 to 2025
$952k
NHGRI NIH HHS U01 HG007278NHGRI NIH HHS U01 HG009610NIDDK NIH HHS K23 DK124645NIDDK NIH HHS R01 DK108803NIH HHS K23DK124645NIH HHS R01DK108803, U01HG007278, U01HG009610, U01DK116100NIH HHS S10 OD026880NIH HHS S10 OD030463NIH HHS T32DK007757
6 · The paper itself

Abstract

introductionEnd-stage kidney disease (ESKD) is associated with increased morbidity and mortality. Identifying patients with stage 4 CKD (CKD4) at risk of rapid progression to ESKD remains challenging. Accurate prediction of CKD4 progression can improve patient outcomes by improving advanced care planning and optimizing healthcare resource allocation.

methodsWe obtained electronic health record data from patients with CKD4 in a large health system between January 1, 2006, and December 31, 2016. We developed and validated four models, including Least Absolute Shrinkage and Selection Operator (LASSO) regression, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network (ANN), to predict ESKD at 3 years. We utilized area under the receiver operating characteristic curve (AUROC) to evaluate model performances and utilized Shapley additive explanation (SHAP) values and plots to define feature dependence of the best performance model.

resultsWe included 3,160 patients with CKD4. ESKD was observed in 538 patients (21%). All approaches had similar AUROCs; ANN yielded the highest AUROC (0.77; 95%CI 0.75 to 0.79) and LASSO regression (0.77; 95%CI 0.75 to 0.79), followed by random forest (0.76; 95% CI 0.74 to 0.79), and XGBoost (0.76; 95% CI 0.74 to 0.78).

conclusionsWe developed and validated several models for near-term prediction of kidney failure in CKD4. ANN, random forest, and XGBoost demonstrated similar predictive performances. Using this suite of models, interventions can be customized based on risk, and population health and resources appropriately allocated.

Indexed as

Kidney Failure, ChronicRenal InsufficiencyRenal Insufficiency, ChronicArea Under CurveHumansMachine LearningArtificial intelligenceChronic Kidney DiseaseEnd-stage Kidney DiseaseMachine learningPrediction model

Identifiers

PMID38114923
PMCPMC10731874
OpenAlexW4389937012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.